2007
DOI: 10.1093/bioinformatics/btm188
|View full text |Cite
|
Sign up to set email alerts
|

Structural templates predict novel protein interactions and targets from pancreas tumour gene expression data

Abstract: Supplementary data are available at Bioinformatics online.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
14
0

Year Published

2008
2008
2016
2016

Publication Types

Select...
4
3
1

Relationship

0
8

Authors

Journals

citations
Cited by 21 publications
(14 citation statements)
references
References 74 publications
0
14
0
Order By: Relevance
“…By means of these methods we could identify four potential interaction partners for KLK6: a-1 antiproteinase, AT III, pigment epithelium-derived factor and synuclein (Table 3). However, no additional interaction partner for KLK10 other than the already described could be identified (Dawelbait et al, 2007).…”
Section: Protein Interaction Predictionmentioning
confidence: 86%
See 1 more Smart Citation
“…By means of these methods we could identify four potential interaction partners for KLK6: a-1 antiproteinase, AT III, pigment epithelium-derived factor and synuclein (Table 3). However, no additional interaction partner for KLK10 other than the already described could be identified (Dawelbait et al, 2007).…”
Section: Protein Interaction Predictionmentioning
confidence: 86%
“…To find possible novel interactions we used structure-and sequence-based prediction of protein interactions as described earlier (Altschul et al, 1997;Mishra et al, 2006;Dawelbait et al, 2007).…”
Section: Protein Interaction Predictionmentioning
confidence: 99%
“…Aytuna et al 11 presented a structure-based method to predict protein–protein interactions using known template interfaces; if surface regions of two proteins are structurally similar to the two sides of a template interface, the two proteins are predicted to interact. More recently, Schroeder and co-workers 6 used structural templates to predict novel protein interactions specific for pancreatic cancer. Several groups have also shown how it is possible to estimate kinetic constants for the binding parameters using structural information.…”
Section: The Concept and Introductionmentioning
confidence: 99%
“…Clinical testing of brivudine in combination with gemcitabine and cisplatin in pancreatic cancer patients improves the efficiency of chemotherapy [36]. The effect of brivudine may be due to down-regulation of Hsp27 activity in tumor cells [37], although other molecular targets are proposed [38]. Affinity chromatography with brivudine-loaded magnetic beads pulls down only Hsp27.…”
Section: Hsp27mentioning
confidence: 99%